Suki AI has closed a $90 million Series E led by Healthier Capital, pushing the ambient-documentation company past 450 healthcare organizations as customers and setting up a pivot from writing clinical notes to running broader AI “agent” tasks inside the exam room, the company said. The round lands in the middle of a crowded field — Abridge, Ambience Healthcare and Microsoft’s Nuance DAX are all chasing the same doctors’ time — and tests whether an AI scribe can become something stickier than a transcription tool before Epic’s own built-in version eats the category from underneath.
From Transcription to Agents
Suki’s pitch has shifted noticeably over the past year. The company started as a voice assistant that turned doctor-patient conversations into structured notes inside the electronic health record, a category now commonly called “ambient AI scribing.” With the new funding, Suki says it plans to extend the same underlying model into tasks like drafting referral letters, prior-authorization paperwork and follow-up messages — work that happens around the visit rather than during it, and that clinicians consistently describe as a bigger source of after-hours burnout than note-taking itself.
A Crowded, Fast-Consolidating Market
The ambient scribe category has seen close to $1 billion in venture investment since 2025, according to healthcare-technology trackers, with Abridge reportedly valued near $5.3 billion after an extended Series E and Ambience Healthcare raised a Series C north of $200 million at roughly $1 billion to $1.25 billion in valuation. Suki’s own numbers are smaller — the company has not disclosed a post-money valuation for this round — but its 450-customer base gives it real distribution among independent practices and mid-size health systems that are price-sensitive compared with the flagship academic medical centers Abridge has targeted.
The Epic Problem Every Scribe Startup Faces
The single biggest competitive threat to every standalone AI scribe company is not each other — it’s Epic Systems, the dominant hospital software vendor, which has built its own ambient documentation tool directly into the EHR that most large U.S. hospitals already run. Health system IT leaders have told industry publications that a free or bundled Epic tool is a hard sell to beat on price alone, which is part of why Suki, Abridge and Ambience are all racing to add capabilities Epic hasn’t matched yet, rather than competing purely on transcription accuracy.
Why Investors Are Still Writing Checks
Healthier Capital’s decision to lead the round signals continued investor appetite for the category despite the competitive crowding, a bet that the total addressable market — every outpatient visit in the U.S., numbering in the hundreds of millions annually — is large enough to support several winners, at least for now. Suki has pointed to physician time savings as its core value proposition, citing internal customer data showing meaningfully reduced documentation time per visit, though like most vendor-reported figures in this space, those numbers have not been independently validated through peer-reviewed research.
What Clinicians Actually Want
Physician groups have been cautiously receptive to ambient scribes specifically because the tool sits in the background during a visit rather than requiring clinicians to change how they interact with patients, a contrast with earlier generations of clinical AI that demanded new workflows. But the expansion into agentic tasks — letting AI draft outbound referrals or insurance paperwork without a human in the loop at every step — raises the same liability and oversight questions that have slowed adoption of AI in other parts of clinical decision-making, including who is accountable when an AI-drafted prior-authorization request contains an error.
What’s Next
Suki says it will use the funding to expand its engineering team focused on agentic workflows and to broaden its health-system partnerships beyond its current base. The real test will come over the next year as Abridge, Ambience and Suki all push into adjacent administrative work simultaneously, turning what started as a note-taking product category into a broader fight over who owns the AI layer of the clinical visit — one that Epic, with its built-in distribution advantage, is positioned to win by default unless the independent vendors can demonstrate a clear capability gap.
Photo: Vitaly Gariev / PEXELS via Pexels
